NASDAQ:SYRE Spyre Therapeutics Q3 2025 Earnings Report $71.01 +1.88 (+2.72%) Closing price 04:00 PM EasternExtended Trading$72.51 +1.50 (+2.12%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Spyre Therapeutics EPS ResultsActual EPS-$0.15Consensus EPS -$0.68Beat/MissBeat by +$0.53One Year Ago EPSN/ASpyre Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.10 millionBeat/MissN/AYoY Revenue GrowthN/ASpyre Therapeutics Announcement DetailsQuarterQ3 2025Date11/4/2025TimeBefore Market OpensConference Call DateTuesday, November 4, 2025Conference Call Time7:00AM ETUpcoming EarningsSpyre Therapeutics' Q2 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Spyre Therapeutics Earnings HeadlinesSpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5 at 8:00 AM | globenewswire.comSheldon Sloan Sells 78,333 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockMay 3 at 5:25 AM | americanbankingnews.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 5 at 1:00 AM | Brownstone Research (Ad)Scott Burrows Sells 12,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockMay 3 at 4:49 AM | americanbankingnews.comCameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockMay 3 at 4:49 AM | americanbankingnews.comSpyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million RaiseMay 1, 2026 | finance.yahoo.comSee More Spyre Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email. Email Address About Spyre TherapeuticsSpyre Therapeutics (NASDAQ:SYRE) is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications. Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts. The company utilizes advanced screening technologies and a modular engineering approach to optimize therapeutic candidates, streamline preclinical development and position its programs for clinical readiness. Based in the United States, Spyre Therapeutics operates a modern research and development facility that supports both in-house projects and external partnerships. Led by a management team experienced in biopharmaceutical innovation and development, the company is working to advance its lead programs into human trials and aims to bring new treatment options to patients with high-need cancers.View Spyre Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
